Clinical trial · Interventional
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
NCT02104986CI-TRIAL-00060585completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective is to assess the benefit-risk ratio of a risk-adapted strategy for treatment of extra cranial NSMGCT in children and adolescent.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extra Cranial Non Seminomateous Malignant Germ Cell Tumour | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Velbe-Bleomycin-Cisplatin | Drug | — | UNRESOLVED |
| Vepeside-ifosfamide-Cisplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- 3 courses of Velbe-Bleomycin-Cisplatin
- description
- 3 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
- interventionNames
- Drug: Velbe-Bleomycin-Cisplatin
- type
- EXPERIMENTAL
- label
- 4 courses of Velbe-Bleomycin-Cisplatin
- description
- 4 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
- interventionNames
- Drug: Velbe-Bleomycin-Cisplatin
- type
- EXPERIMENTAL
- label
- 3 courses Vepeside-ifosfamide-Cisplatin
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Extra cranial non seminomateous malignant germ cell tumour (NSMGCT) except pure immature teratoma. * Age ≤ 18 years. * Affiliation with a social security scheme. * Signed informed consent by parents * Effective contraception during the study if relevant . Exclusion Criteria: * Previous chemotherapy * Contraindications to study treatments * Patient who cannot follow medical surveillance due to geographical, social, or psychological reasons * Pregnant and breast feeding women
References
Publications (0)
Data not yet available
No reference posted for this study.